Page last updated: 2024-12-06
nanterinone
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
nanterinone: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
---|---|
PubMed CID | 71305 |
CHEMBL ID | 37971 |
SCHEMBL ID | 563806 |
MeSH ID | M0170593 |
Synonyms (24)
Synonym |
---|
102791-47-9 |
uk-61260 |
uk-61260-27 |
nanterinone |
CHEMBL37971 |
6-(2,4-dimethylimidazol-1-yl)-8-methyl-1h-quinolin-2-one |
uk-61,260 |
nanterinone [inn:ban] |
2(1h)-quinolinone, 6-(2,4-dimethyl-1h-imidazol-1-yl)-8-methyl- |
6-(2,4-dimethylimidazol-1-yl)-8-methyl-2-quinolone |
unii-1s169l7kav |
1s169l7kav , |
nanterinone [inn] |
nanterinone [mart.] |
2(1h)-quinolinone,6-(2,4-dimethyl-1h-imidazol-1-yl)-8-methyl- |
SCHEMBL563806 |
8-methyl-6-(2,4-dimethylimidazol-1-yl)-2-(1h)-quinolone |
8-methyl-6-(2,4-dimethylimidazol1-yl)-2-(1h)-quinolone |
NMNXBEXPAHSXOK-UHFFFAOYSA-N |
DTXSID70145513 |
6-(2,4-dimethyl-1h-imidazol-1-yl)8-meth-yl-2(1h)-quinolone |
6-(2,4-dimethyl-1h-imidazol-1-yl)-8-methylquinolin-2(1h)-one |
Q27252817 |
AKOS040753210 |
Research Excerpts
Overview
Nanterinone (UK-61,260) is a novel positive inotropic and balanced-type vasodilating drug. Only partially based on phosphodiesterase III inhibition.
Excerpt | Reference | Relevance |
---|---|---|
"Nanterinone (UK-61,260) is a novel positive inotropic and balanced-type vasodilating drug, only partially based on phosphodiesterase III inhibition. " | ( Acute hemodynamic effects and preload-dependent cardiovascular profile of the partial phosphodiesterase inhibitor nanterinone in patients with mild to moderate heart failure. Bartels, GL; Krauss, XH; Kruijssen, HA; Remme, WJ; Storm, CJ; van der Ent, M; van Hoogenhuyze, DC; van Schelven, D, 1996) | 1.95 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Bioassays (9)
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID58757 | Relative inotropic potency compared with 4-[4-[2-(1,1-dioxo-2-isothiazolidinyl)ethyl]-1-piperidinyl]-6,7-dimethoxyquinazoline at 50 ug/kg after administration at 12.5 ug/kg intravenously to anesthetized dogs | 1989 | Journal of medicinal chemistry, Mar, Volume: 32, Issue:3 | 2(1H)-quinolinones with cardiac stimulant activity. 2. Synthesis and biological activities of 6-(N-linked, five-membered heteroaryl) derivatives. |
AID25583 | Dissociation constant was determined | 1989 | Journal of medicinal chemistry, Sep, Volume: 32, Issue:9 | 7-Heteroaryl-1,2,3,5-tetrahydroimidazo[2,1-b]quinazolin -2(1H)-one derivatives with cardiac stimulant activity. |
AID60036 | Compound was tested for cardiotonic activity after intravenous administration of 12.5 ug/Kg to anesthetized dogs | 1989 | Journal of medicinal chemistry, Mar, Volume: 32, Issue:3 | 2(1H)-quinolinones with cardiac stimulant activity. 2. Synthesis and biological activities of 6-(N-linked, five-membered heteroaryl) derivatives. |
AID60659 | 0.25 mg/kg of compound was administered orally to conscious adult Beagle dogs and the effects on cardiac contractility was determined after 1 hr | 1989 | Journal of medicinal chemistry, Jul, Volume: 32, Issue:7 | 2(1H)-quinolinones with cardiac stimulant activity. 3. Synthesis and biological properties of 6-imidazol-1-yl derivatives. |
AID60796 | Compound was examined for effects on cardiac contractility after oral administration of 0.25 mg/Kg to conscious dogs for 1 hr | 1989 | Journal of medicinal chemistry, Mar, Volume: 32, Issue:3 | 2(1H)-quinolinones with cardiac stimulant activity. 2. Synthesis and biological activities of 6-(N-linked, five-membered heteroaryl) derivatives. |
AID60801 | Compound was examined for effects on cardiac contractility to decrease in QA interval after oral administration of 0.25 mg/Kg to conscious dogs for 3h | 1989 | Journal of medicinal chemistry, Mar, Volume: 32, Issue:3 | 2(1H)-quinolinones with cardiac stimulant activity. 2. Synthesis and biological activities of 6-(N-linked, five-membered heteroaryl) derivatives. |
AID58749 | Inotropic potencies relative to 4-[4-[2-(1,1-dioxo-2-isothiazolidinyl)ethyl]-1-piperidinyl]-6,7-dimethoxyquinazoline (50 ug/kg) in anesthetized dog | 1989 | Journal of medicinal chemistry, Jul, Volume: 32, Issue:7 | 2(1H)-quinolinones with cardiac stimulant activity. 3. Synthesis and biological properties of 6-imidazol-1-yl derivatives. |
AID60786 | 0.25 mg/kg of compound was administered orally to conscious adult Beagle dogs and the effects on cardiac contractility was determined after 3 hr | 1989 | Journal of medicinal chemistry, Jul, Volume: 32, Issue:7 | 2(1H)-quinolinones with cardiac stimulant activity. 3. Synthesis and biological properties of 6-imidazol-1-yl derivatives. |
AID59896 | Positive inotropic activity after intravenous administration of 12.5 ug/kg (dose) to anesthetized dog | 1989 | Journal of medicinal chemistry, Jul, Volume: 32, Issue:7 | 2(1H)-quinolinones with cardiac stimulant activity. 3. Synthesis and biological properties of 6-imidazol-1-yl derivatives. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Research
Studies (8)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 4 (50.00) | 18.7374 |
1990's | 3 (37.50) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (12.50) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 11.85
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (11.85) All Compounds (24.57) |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 1 (12.50%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 7 (87.50%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |